Michael Barbella, Managing Editor04.05.23
Bioventus Inc. CEO and board member Ken M. Reali has stepped down from his positions. The company did not provide a reason Reali left the firm, nor did it specify an exact date for his departure.
"On behalf of the board and Bioventus employees, I want to thank Ken for his valuable contributions to Bioventus and his dedicated leadership over the past three years," Executive Board Chairman William A. Hawkins said. "We are urgently looking to address our performance and execution, unlock long-term value and deliver on the expectations of our shareholders."
The board has initiated a comprehensive search process to identify a permanent CEO but appointed Anthony Bihl as interim chief executive, effective immediately. Bihl has more than 35 years of industry experience, having formerly served as Bioventus CEO and board member from 2013 until his retirement in 2020. Bihl currently serves as a board member for Sonendo Inc. and Spectral Medical Inc.
"As we search for a permanent successor, we believe Tony is uniquely positioned as the interim CEO to lead Bioventus through this transition given his previous experience, tenure and success at the company,” Hawkins stated.
“I look forward to working closely with the board and executive leadership team as interim CEO. Bioventus has a strong foundation, a differentiated portfolio of leading products that drive value for patients, and significant potential across large and growing addressable markets," Bihl said. "I look forward to leveraging my prior executive leadership experience to stabilize the company, improve execution, and enhance shareholder value as we deliver on the company’s mission.”
Durham, N.C.-based Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its innovations include offerings for pain treatments, restorative therapies, and surgical solutions.
"On behalf of the board and Bioventus employees, I want to thank Ken for his valuable contributions to Bioventus and his dedicated leadership over the past three years," Executive Board Chairman William A. Hawkins said. "We are urgently looking to address our performance and execution, unlock long-term value and deliver on the expectations of our shareholders."
The board has initiated a comprehensive search process to identify a permanent CEO but appointed Anthony Bihl as interim chief executive, effective immediately. Bihl has more than 35 years of industry experience, having formerly served as Bioventus CEO and board member from 2013 until his retirement in 2020. Bihl currently serves as a board member for Sonendo Inc. and Spectral Medical Inc.
"As we search for a permanent successor, we believe Tony is uniquely positioned as the interim CEO to lead Bioventus through this transition given his previous experience, tenure and success at the company,” Hawkins stated.
“I look forward to working closely with the board and executive leadership team as interim CEO. Bioventus has a strong foundation, a differentiated portfolio of leading products that drive value for patients, and significant potential across large and growing addressable markets," Bihl said. "I look forward to leveraging my prior executive leadership experience to stabilize the company, improve execution, and enhance shareholder value as we deliver on the company’s mission.”
Durham, N.C.-based Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its innovations include offerings for pain treatments, restorative therapies, and surgical solutions.